- Preview Available
- Scholarly Journal
Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)
Blood Cancer Journal; London Vol. 15, Iss. 1, (Dec 2025): 42.
DOI:10.1038/s41408-025-01223-x
This is a limited preview of the full PDF
Try and log in through your library or institution to see if they have access.